Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

Eva Gimeno; Blanca Sánchez-González; Alberto Álvarez-Larrán; Carmen Pedro; Eugenia Abella; Josep Comín; Silvia Saumell; Francesc García-Pallarols; Miquel Gómez; Carles Besses; Antonio Salar

doi:10.1016/j.leukres.2010.07.024

Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

Eva Gimeno, Blanca Sánchez-González, Alberto Álvarez-Larrán, Carmen Pedro, Eugenia Abella, Josep Comín, Silvia Saumell, Francesc García-Pallarols, Miquel Gómez, Carles Besses, Antonio Salar

Departament de Medicina

Producció científica: Contribució a una revista › Article › Recerca › Avaluat per experts

18 Cites (Scopus)

Resum

Doxorubicin-containing chemotherapy is the standard regimen for elderly patients with aggressive lymphoma. However, many of them cannot receive it due to severe associated comorbidities. Toxicity and efficacy of intermediate doses of nonpegylated liposomal doxorubicin (NPLD) in modified-CHOP regimen±Rituximab were prospectively analyzed in 35 frail elderly patients (median age: 76 years) with previously untreated aggressive lymphoma with one or more severe comorbidities. NPLD at intermediate doses (30mg/m2) is effective and well tolerated in these patients. In addition, NT-proBNP levels >900ng/ml at diagnosis have demonstrated to be a good predictor for OS and PFS in this cohort of patients. © 2010 Elsevier Ltd.

Idioma original	English
Pàgines (de-a)	358-362
Revista	Leukemia Research
Volum	35
Número	3
DOIs	https://doi.org/10.1016/j.leukres.2010.07.024
Estat de la publicació	Publicada - 1 de març 2011

Accés al document

10.1016/j.leukres.2010.07.024

Com citar-ho

Gimeno, E., Sánchez-González, B., Álvarez-Larrán, A., Pedro, C., Abella, E., Comín, J., Saumell, S., García-Pallarols, F., Gómez, M., Besses, C., & Salar, A. (2011). Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leukemia Research, 35(3), 358-362. https://doi.org/10.1016/j.leukres.2010.07.024

@article{4618e394ee374f4bb231cf4309b6a03b,

title = "Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma",

abstract = "Doxorubicin-containing chemotherapy is the standard regimen for elderly patients with aggressive lymphoma. However, many of them cannot receive it due to severe associated comorbidities. Toxicity and efficacy of intermediate doses of nonpegylated liposomal doxorubicin (NPLD) in modified-CHOP regimen±Rituximab were prospectively analyzed in 35 frail elderly patients (median age: 76 years) with previously untreated aggressive lymphoma with one or more severe comorbidities. NPLD at intermediate doses (30mg/m2) is effective and well tolerated in these patients. In addition, NT-proBNP levels >900ng/ml at diagnosis have demonstrated to be a good predictor for OS and PFS in this cohort of patients. {\textcopyright} 2010 Elsevier Ltd.",

keywords = "Aggressive lymphoma, Chemotherapy, Elderly, Frail population, Nonpegylated liposomal doxorubicin",

author = "Eva Gimeno and Blanca S{\'a}nchez-Gonz{\'a}lez and Alberto {\'A}lvarez-Larr{\'a}n and Carmen Pedro and Eugenia Abella and Josep Com{\'i}n and Silvia Saumell and Francesc Garc{\'i}a-Pallarols and Miquel G{\'o}mez and Carles Besses and Antonio Salar",

year = "2011",

month = mar,

day = "1",

doi = "10.1016/j.leukres.2010.07.024",

language = "English",

volume = "35",

pages = "358--362",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "3",

}

Gimeno, E, Sánchez-González, B, Álvarez-Larrán, A, Pedro, C, Abella, E, Comín, J, Saumell, S, García-Pallarols, F, Gómez, M, Besses, C & Salar, A 2011, 'Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma', Leukemia Research, vol. 35, núm. 3, pàg. 358-362. https://doi.org/10.1016/j.leukres.2010.07.024

Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. / Gimeno, Eva; Sánchez-González, Blanca; Álvarez-Larrán, Alberto et al.
In: Leukemia Research, Vol. 35, Núm. 3, 01.03.2011, pàg. 358-362.

Producció científica: Contribució a una revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

AU - Gimeno, Eva

AU - Sánchez-González, Blanca

AU - Álvarez-Larrán, Alberto

AU - Pedro, Carmen

AU - Abella, Eugenia

AU - Comín, Josep

AU - Saumell, Silvia

AU - García-Pallarols, Francesc

AU - Gómez, Miquel

AU - Besses, Carles

AU - Salar, Antonio

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Doxorubicin-containing chemotherapy is the standard regimen for elderly patients with aggressive lymphoma. However, many of them cannot receive it due to severe associated comorbidities. Toxicity and efficacy of intermediate doses of nonpegylated liposomal doxorubicin (NPLD) in modified-CHOP regimen±Rituximab were prospectively analyzed in 35 frail elderly patients (median age: 76 years) with previously untreated aggressive lymphoma with one or more severe comorbidities. NPLD at intermediate doses (30mg/m2) is effective and well tolerated in these patients. In addition, NT-proBNP levels >900ng/ml at diagnosis have demonstrated to be a good predictor for OS and PFS in this cohort of patients. © 2010 Elsevier Ltd.

AB - Doxorubicin-containing chemotherapy is the standard regimen for elderly patients with aggressive lymphoma. However, many of them cannot receive it due to severe associated comorbidities. Toxicity and efficacy of intermediate doses of nonpegylated liposomal doxorubicin (NPLD) in modified-CHOP regimen±Rituximab were prospectively analyzed in 35 frail elderly patients (median age: 76 years) with previously untreated aggressive lymphoma with one or more severe comorbidities. NPLD at intermediate doses (30mg/m2) is effective and well tolerated in these patients. In addition, NT-proBNP levels >900ng/ml at diagnosis have demonstrated to be a good predictor for OS and PFS in this cohort of patients. © 2010 Elsevier Ltd.

KW - Aggressive lymphoma

KW - Chemotherapy

KW - Elderly

KW - Frail population

KW - Nonpegylated liposomal doxorubicin

U2 - 10.1016/j.leukres.2010.07.024

DO - 10.1016/j.leukres.2010.07.024

M3 - Article

SN - 0145-2126

VL - 35

SP - 358

EP - 362

JO - Leukemia Research

JF - Leukemia Research

IS - 3

ER -

Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

Resum

Accés al document

Fingerprint

Com citar-ho